Aquestive Therapeutics, Inc. (AQST)

Insider Trading Filed: 2026-04-13

Key Insights

• Insider Daniel Barber, who serves as the President and CEO of Aquestive Therapeutics, acquired 293,100 performance stock units (PSUs) on March 7, 2025. The PSUs will vest on March 7, 2028, contingent on the company's stock price performance.
• The PSUs have a performance period from March 7, 2025 to March 7, 2028, with vesting based on the highest 30-day average Nasdaq closing price during the period. This suggests Barber's compensation is closely tied to the company's long-term stock price appreciation.
• The Form 4 filing was submitted late due to an inadvertent administrative oversight, which may raise some concerns about the company's reporting processes.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-13

Key Insights

• The reporting person, Peter E. Boyd, acquired 60,000 performance stock units (PSUs) on March 7, 2025, which will vest 100% on March 7, 2028 based on certain performance criteria.
• The acquisition of the PSUs indicates that the reporting person, who is the Chief People Officer, has a vested interest in the long-term performance of the company.
• The filing was submitted late due to an inadvertent administrative oversight, which could raise concerns about the company's internal controls and reporting processes.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-13

Key Insights

• The reporting person, Cassie Jung, has acquired 60,000 performance stock units (PSUs) of Aquestive Therapeutics, Inc. on March 7, 2025. This indicates potential confidence in the company's future performance.
• The PSUs are subject to a three-year vesting period, which aligns the reporting person's interests with long-term shareholders.
• The reporting person is the Chief Operating Officer of Aquestive Therapeutics, Inc., suggesting insider knowledge and involvement in the company's strategic direction.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-13

Key Insights

• The reporting person, A. Ernest Toth Jr., acquired 82,500 performance stock units (PSUs) on 03/07/2025, which vest 100% on 03/07/2028 based on the company's stock price performance.
• The PSUs represent a significant equity award for the SVP and Chief Financial Officer, potentially aligning his interests with those of shareholders.
• The transaction was filed late due to an inadvertent administrative oversight, which could raise questions about the company's internal reporting processes.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-04-13

Key Insights

• Sherry Korczynski, the Chief Commercial Officer of Aquestive Therapeutics, Inc., has acquired 67,500 performance stock units (PSUs) that will vest on March 7, 2028 based on the company's stock price performance.
• The PSUs represent a long-term incentive for Korczynski to drive the company's growth and increase shareholder value over the next three years.
• The filing of this Form 4 was delayed due to an inadvertent administrative oversight, indicating potential areas for improvement in the company's reporting processes.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-13

Key Insights

• Lori J. Braender, the Corporate Secretary of Aquestive Therapeutics, Inc. (AQST), acquired 82,500 Performance Stock Units (PSUs) on March 7, 2025, which vest on March 7, 2028 based on the company's stock price performance.
• The PSUs awarded to Lori J. Braender represent a long-term incentive that aligns her interests with those of the shareholders, as the vesting is tied to the company's stock price performance over a three-year period.
• The SEC Form 4 filing was submitted late due to an inadvertent administrative oversight, but this does not appear to raise any major concerns about the company's governance or insider trading activities.

Sentiment: Positive Significance: 5/10

View Original Filing →

Current Report Filed: 2026-03-30

Key Insights

• Aquestive Therapeutics received preliminary comments and successfully completed a Type A meeting with the FDA regarding the resubmission of its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type 1 allergic reactions, including anaphylaxis.
• The successful completion of the FDA meeting indicates progress in the regulatory approval process for Anaphylm, a potential treatment for a serious medical condition.
• Investors should monitor further updates on the NDA resubmission and the FDA's review process, as the approval of Anaphylm could be a significant milestone for the company.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-03-20

Key Insights

• Aquestive Therapeutics has announced the departure of its Chief Legal Officer and Chief Compliance Officer, Lori J. Braender, effective April 2, 2026. The company has appointed Thomas A. Zalewski as the new Chief Legal Officer and Chief Compliance Officer.
• Braender will remain with the company in a transition role until May 7, 2026, and will continue to serve as the Corporate Secretary through at least year-end. She will be entitled to severance benefits, including a pro-rata bonus, salary continuation, and full vesting of her equity awards.
• The leadership change and transition terms outlined in the 8-K filing suggest that the departure of the Chief Legal Officer and Chief Compliance Officer is a planned and amicable event, which may provide stability and continuity for the company's legal and compliance functions.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• The reporting person, Daniel Barber, the President and CEO of Aquestive Therapeutics, Inc., acquired 262,000 shares of common stock on March 9, 2026, which will vest in three annual installments.
• On March 10, 2026, the reporting person sold 180,677 shares to cover tax withholding obligations in connection with the vesting of restricted stock units, as mandated by the company's equity incentive plans.
• The reporting person was granted 523,000 non-qualified stock options on March 9, 2026, which will also vest in three annual installments.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• Peter E. Boyd, the Chief People Officer, was granted 80,000 shares of restricted stock and 42,500 non-qualified stock options, indicating the company's commitment to retaining key personnel.
• Boyd sold 29,814 shares to cover tax withholding obligations, suggesting he is managing his equity compensation in a prudent manner.
• The vesting schedules for the restricted stock and stock options are structured in three annual installments, aligning Boyd's incentives with the company's long-term performance.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• Lori J. Braender, the Chief Legal Officer of Aquestive Therapeutics, Inc., acquired 80,000 shares of common stock through a restricted stock award, indicating management's confidence in the company's future.
• Braender also sold 40,102 shares to cover tax withholding obligations, which is a common practice for executives receiving equity-based compensation.
• The company granted Braender a non-qualified stock option to purchase 50,000 shares of common stock, further aligning her interests with those of shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• Melina Cioffi, SVP of Regulatory Affairs, acquired 100,000 shares of Aquestive Therapeutics common stock, indicating insider confidence in the company's prospects.
• Cioffi also sold 25,311 shares to cover tax withholding obligations, a common practice for equity awards, suggesting no major concerns.
• Cioffi was granted 75,000 stock options with a $4.29 exercise price, further aligning her incentives with long-term shareholder value creation.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• The CFO, A. Ernest Toth Jr., acquired 95,000 restricted shares of Aquestive Therapeutics, Inc. (AQST) through an equity award, indicating management's confidence in the company's future performance.
• Toth also sold 58,254 shares to cover tax withholding obligations, likely a routine transaction related to the vesting of equity awards.
• Toth was granted 70,000 non-qualified stock options with a strike price of $4.29, further aligning his interests with those of shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• The Chief Commercial Officer, Sherry Korczynski, acquired 75,000 shares of Aquestive Therapeutics, Inc. (AQST) on March 9, 2026, indicating their confidence in the company's future prospects.
• Korczynski also sold 15,741 shares on March 10, 2026, likely to cover tax withholding obligations related to the vesting of restricted stock units, which is a common practice.
• Korczynski was granted 42,500 non-qualified stock options with a strike price of $4.29, which will vest in three annual installments, further aligning their interests with those of shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• Cassie Jung, the Chief Operating Officer, acquired 80,000 shares of Aquestive Therapeutics, Inc. (AQST) stock through a restricted stock grant, increasing her direct ownership to 320,771 shares.
• Jung also sold 45,791 shares to cover tax withholding obligations, suggesting a focus on managing her equity position in the company.
• The company granted Jung 42,500 non-qualified stock options with a 10-year expiration, indicating continued executive compensation and incentive alignment.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• The filing indicates that Matthew W. Davis, the Chief Development Officer of Aquestive Therapeutics, Inc. (AQST), acquired 50,000 shares of the company's common stock through a restricted stock grant, which will vest in three annual installments.
• Additionally, Davis was granted a non-qualified stock option to purchase 50,000 shares of the company's common stock, which will also vest in three annual installments.
• The timing of these insider transactions suggests that Davis is confident in the company's future prospects and is aligning his interests with those of shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-11

Key Insights

• Insider Matthew J. Greenhawt, the Chief Medical Officer, has acquired 75,000 shares of Aquestive Therapeutics, Inc. (AQST) common stock, indicating potential confidence in the company's future performance.
• The awarded non-qualified stock options with a strike price of $4.29 and a 10-year expiration date suggest Greenhawt's long-term alignment with shareholder interests.
• The vesting schedule of the stock grant and options, with 25% vesting in the first year and 50% in the third year, aligns with the company's long-term growth strategy.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-02-26

Key Insights

• Aquestive Therapeutics, Inc. is furnishing an investor presentation, which provides an update on the company's business and financial performance.
• The presentation is being shared with institutional investors, analysts, and others, indicating the company is actively engaging with the investment community.
• The availability of the presentation on the company's website suggests transparency and a desire to share information with shareholders and potential investors.

Sentiment: Positive Significance: 5/10

View Original Filing →

Current Report Filed: 2026-01-09

Key Insights

• The FDA has identified deficiencies in Aquestive Therapeutics' New Drug Application (NDA) for its product candidate Anaphylm, which could result in a delay in potential FDA approval.
• The company is working to understand and resolve the FDA's concerns prior to the scheduled PDUFA goal date of January 31, 2026.
• Aquestive Therapeutics is continuing to advance its global strategy for Anaphylm, with plans to seek regulatory approval in Canada and Europe in 2026.

Sentiment: Negative Significance: 6/10

View Original Filing →